SCN1A variations and response to multiple antiepileptic drugs.
T S C YipC O'DohertyChoon Kiat Nigel TanL M DibbensV SuppiahPublished in: The pharmacogenomics journal (2013)
In the current study, we have used the haplotype-tagging single-nucleotide polymorphisms (SNPs) to determine associations between genetic variants in SCN1A and treatment response in 519 Caucasian patients with known response status for epilepsy treated with antiepileptic drugs (AEDs) with sodium channel blocking effects. Nine SNPs within SCN1A were genotyped in this cohort. The only association observed was for rs10188577. A greater proportion of drug-resistant patients were heterozygous compared with drug responsive patients (48.3% vs 35.4%, P=0.014). After correction for potential confounding factors, the association for rs10188577 was only marginally significant (P=0.049). In light of our findings, it seems unlikely that rs10188577 could be a major determinant of response to AEDs. However, looking at the influence of rs10188577 on the expressed quantitative trait association patterns within the immediate vicinity of SCN1A, we found significant associations with neighbouring sodium channel genes, SCN7A and SCN9A (P<0.025), which warrants further studies.
Keyphrases
- drug resistant
- end stage renal disease
- newly diagnosed
- chronic kidney disease
- genome wide
- ejection fraction
- multidrug resistant
- peritoneal dialysis
- prognostic factors
- emergency department
- acinetobacter baumannii
- dna methylation
- risk assessment
- cancer therapy
- patient reported outcomes
- pseudomonas aeruginosa
- early onset
- drug delivery